Rankings
Pricing
Log In
Free Trial
US-listed companies
Vor Biopharma Inc.
Vor Biopharma Inc.
VOR
Market cap
$45.52M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2021
Dec 31,
2022
Net loss
-69
-92
Depreciation
1
3
Non-cash lease expense
3
6
Stock-based compensation
4
11
Other
0
-0
Operating lease liability
-3
-13
Prepaid expenses and other current assets
6
-0
Accounts payable and accrued liabilities
0
1
Other assets
1
1
Net cash used in operating activities
-69
-85
Purchases of marketable securities
-
123
Proceed from maturities of marketable securities
-
38
Purchases of property and equipment
4
8
Net cash used in investing activities
-92
-94
Proceeds from issuance of redeemable convertible preferred stock
45
-
Proceeds from Issuance Initial Public Offering
189
-
Payment of initial public offering costs
2
-
Proceeds From Issuance Initial Public Offering And Concurrent Private Placement
-
112
Proceeds from Issuance of Common Stock
-
4
Proceeds from stock option exercises and issuance of common stock under ESPP
-
1
Net cash provided by financing activities
233
117
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents
72
-62
Lease Incentive Paid By Landlord
-
8
Operating right-of-use assets and operating lease liability recorded upon lease commencement
0
23
Capital Expenditures Incurred but Not yet Paid
0
0
Financing costs associated with the sale of common stock included in accounts payable and accrued expenses
-
1
Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering
153
-